MCL

A major winter storm will move across the West Coast and Upper Midwest through Thursday, Feb. 23. We are monitoring and tracking the situation with our logistics partners to minimize challenges. 

On this episode of Mayo Clinic Laboratories “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, sits down with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton to delve deeper into the world of outreach program management. As true pioneers of the department at Mayo Clinic, Ellen and Brianne share their robust knowledge and experience on the journey to becoming an outreach leader.

In this month's "Hot Topic," Eoin Flanagan, M.B., B. Ch., discusses the important issue of autoimmune encephalitis misdiagnosis and identifies red flags that be useful in clinical practice to suggest alternative diagnoses and highlight antibodies that sometimes cause confusion.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., speaks with Dr. Nour Al-Mozain, a hematopathologist and transfusion medicine consultant at King Faisal Specialist Hospital in Riyadh, Saudi Arabia, about the importance of reaching out to colleagues for advice.

Outreach management is not taught in a formal training program. The path can be diverse, with different means and methods for success. Whether you inherited an outreach program or have built one from the ground up, here are seven tips to improve your success.

Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.

This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for February include the following sub-specialties: Clinical Informatics, Cytogenetics, Endocrine Pathology, Hematopathology, and Laboratory Genetics and Genomics.

Mayo Clinic Laboratories expanded movement disorders panel better identifies autoimmune conditions. Four recently identified biomarkers — septin-5, septin-7, neurochondrin, and adaptor protein-3B2 — have been added to the panel, and all four have been shown to respond to immunotherapy.

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.

In this month's "Hot Topic," Elitza Theel, Ph.D., shares the recommended approach to serologic testing for assessment or infection with coccidioides.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Cori Berg, M.S.N., R.N., instructor in nursing for the Center for Individualized[...]

This page includes updates posted to the site during the month of January.

Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.